Q-omics provides the consensus-scored SYT4 profile across patient tissues and cancer cell-line models. SYT4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SYT4 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, SYT4 RNA expression shows 13,045 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, COAD, and TGCT as cancer lineages where SYT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT4 survival associations across molecular data types. SYT4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT4 RNA expression–survival associations across cancer types. High SYT4 expression shows unfavorable associations in UCEC, UVM, STAD and LUSC, but favorable associations in LGG and MESO. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SYT4 RNA expression.
This table summarizes SYT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SYT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT4 shows lower tumor expression in COAD, THCA, KIRC, LUSC, KIRP and LIHC. The COAD box plot shows higher SYT4 RNA expression in normal versus tumor tissue (log2 FC = −1.036, t-test p < 0.001).
This table shows molecular features associated with SYT4 in patient tissues and cancer cell lines. In patient samples, SYT4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
